Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock

超越數字：18位分析師討論再生元製藥公司的股票

Benzinga · 01/28 13:00

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish.

在過去的三個月中，18位分析師分享了他們對Regeneron Pharmicals（納斯達克股票代碼：REGN）的評估，揭示了從看漲到看跌的不同前景。

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

下表簡要介紹了他們最近的評級，顯示了過去30天中情緒的變化，並將其與前幾個月進行了比較。

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high estimate of $1215.00, and a low estimate of $165.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 15.71%.

分析師已經爲Regeneron Pharmicals設定了12個月的目標股價，顯示平均目標股價爲945.56美元，最高估計爲1215.00美元，低估值爲165.00美元。隨着分析師將平均目標股價下調了15.71％，情緒的負面轉變顯而易見。

Diving into Analyst Ratings: An In-Depth Exploration

深入研究分析師評級：深入探索

The standing of Regeneron Pharmaceuticals among...

通過對分析師...

登入免費觀看全文

登入/註冊

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息